The Fort Worth Press - The scientist rewriting DNA, and the future of medicine

USD -
AED 3.673015
AFN 72.335392
ALL 89.301838
AMD 390.703302
ANG 1.790208
AOA 916.497429
ARS 1076.433241
AUD 1.615679
AWG 1.8
AZN 1.703144
BAM 1.766007
BBD 2.019991
BDT 121.555243
BGN 1.767024
BHD 0.376929
BIF 2973.958898
BMD 1
BND 1.336909
BOB 6.912867
BRL 5.8593
BSD 1.00047
BTN 86.155305
BWP 14.110285
BYN 3.274009
BYR 19600
BZD 2.009589
CAD 1.40832
CDF 2874.999842
CHF 0.839095
CLF 0.025602
CLP 982.430208
CNY 7.35005
CNH 7.32492
COP 4302.25
CRC 514.411095
CUC 1
CUP 26.5
CVE 99.564774
CZK 22.656993
DJF 177.973218
DKK 6.73631
DOP 61.951457
DZD 133.173001
EGP 51.328902
ERN 15
ETB 131.931846
EUR 0.902295
FJD 2.30475
FKP 0.783049
GBP 0.773795
GEL 2.755032
GGP 0.783049
GHS 15.506095
GIP 0.783049
GMD 71.501319
GNF 8660.201539
GTQ 7.718494
GYD 209.304005
HKD 7.760619
HNL 25.919438
HRK 6.805103
HTG 130.656987
HUF 367.026994
IDR 16833.5
ILS 3.77972
IMP 0.783049
INR 86.152998
IQD 1310.542854
IRR 42100.000138
ISK 130.55998
JEP 0.783049
JMD 158.279683
JOD 0.708901
JPY 145.525
KES 129.650506
KGS 87.450098
KHR 4006.356717
KMF 449.505548
KPW 900.013215
KRW 1454.904951
KWD 0.307501
KYD 0.833695
KZT 516.185248
LAK 21672.430451
LBP 89638.190864
LKR 297.161123
LRD 200.083071
LSL 19.436824
LTL 2.95274
LVL 0.60489
LYD 5.559644
MAD 9.47117
MDL 17.772781
MGA 4546.316445
MKD 55.572868
MMK 2099.267437
MNT 3510.035407
MOP 7.997093
MRU 39.579947
MUR 45.107636
MVR 15.409785
MWK 1734.788321
MXN 20.43262
MYR 4.468006
MZN 63.901994
NAD 19.436649
NGN 1598.97012
NIO 36.813306
NOK 10.811275
NPR 137.850796
NZD 1.753145
OMR 0.384998
PAB 1.000461
PEN 3.718081
PGK 4.073211
PHP 57.347499
PKR 280.622223
PLN 3.839473
PYG 8012.858136
QAR 3.646871
RON 4.491306
RSD 105.713963
RUB 84.791564
RWF 1441.741612
SAR 3.754089
SBD 8.323254
SCR 14.469099
SDG 600.501786
SEK 9.94266
SGD 1.336298
SHP 0.785843
SLE 22.76005
SLL 20969.501083
SOS 571.748474
SRD 36.9425
STD 20697.981008
SVC 8.754108
SYP 13002.318778
SZL 19.426084
THB 34.076013
TJS 10.869722
TMT 3.51
TND 3.049175
TOP 2.342099
TRY 37.912597
TTD 6.792899
TWD 32.807298
TZS 2668.744983
UAH 41.452848
UGX 3686.748293
UYU 42.971431
UZS 12979.015422
VES 73.26593
VND 25765
VUV 126.180859
WST 2.884176
XAF 592.291578
XAG 0.032305
XAU 0.00032
XCD 2.70255
XDR 0.742612
XOF 592.302275
XPF 107.685918
YER 245.302791
ZAR 19.41145
ZMK 9001.203383
ZMW 28.207027
ZWL 321.999592
  • RBGPF

    -7.7300

    60.27

    -12.83%

  • BCC

    -4.0650

    94.375

    -4.31%

  • GSK

    -1.0650

    33.415

    -3.19%

  • CMSC

    -0.2530

    22.347

    -1.13%

  • RELX

    -0.0800

    48.46

    -0.17%

  • JRI

    -0.2600

    11.73

    -2.22%

  • SCS

    -0.3250

    10.285

    -3.16%

  • NGG

    0.1700

    65.38

    +0.26%

  • RIO

    -0.8800

    54.73

    -1.61%

  • CMSD

    -0.2900

    22.46

    -1.29%

  • BCE

    -0.1200

    20.88

    -0.57%

  • RYCEF

    -0.0900

    9.11

    -0.99%

  • AZN

    -1.8600

    64.9

    -2.87%

  • BTI

    -0.2350

    39.975

    -0.59%

  • VOD

    -0.1150

    8.465

    -1.36%

  • BP

    -1.3000

    26.6

    -4.89%

The scientist rewriting DNA, and the future of medicine
The scientist rewriting DNA, and the future of medicine / Photo: © Broad Institute of Harvard and MIT,/AFP

The scientist rewriting DNA, and the future of medicine

A revolution is underway in gene editing -- and at its forefront is David Liu, an American molecular biologist whose pioneering work is rewriting the building blocks of life with unprecedented precision.

Text size:

A professor at the Broad Institute of MIT and Harvard, Liu was awarded a Breakthrough Prize in Life Sciences on Saturday for developing two transformative technologies: one already improving the lives of patients with severe genetic diseases, the other poised to reshape medicine in the years ahead.

He spoke with AFP ahead of the Los Angeles ceremony for the prestigious Silicon Valley-founded award.

He will receive $3 million for his work on "base editing" and "prime editing," and plans to donate most of it to support his charitable foundation.

"The ability to change a DNA sequence of our choosing into a new sequence of our choosing is a fundamentally very powerful capability," the 51-year-old said, foreseeing uses not just in human medicine but areas like developing more nutritious or disease-resistant crops.

- Correcting the code -

DNA is made up of four chemical "letters" -- the nucleotide bases A, G, T and C. Mutations in this sequence cause thousands of human diseases, yet until recently, gene editing could only fix a limited number of them.

Even CRISPR-Cas9, the groundbreaking technology that earned a Nobel Prize in 2020, has major limitations.

It cuts both strands of the DNA helix, making it most useful to disrupt rather than correct genes, while the process can introduce new errors.

"Being able to use genome editing to treat genetic diseases requires, in most cases, ways to correct a DNA misspelling, not simply to disrupt a gene," Liu said.

That insight led his lab to develop base editing, which uses the Cas9 protein -- disabled so it can no longer cut both DNA strands -- to find a target DNA sequence and another enzyme to convert one letter to another -- for example, C to T or G to A.

Reversing the change -- from T to C or A to G -- was tougher. Liu's team overcame the challenge by engineering entirely new enzymes.

These base editors can now correct about 30 percent of the mutations that cause genetic diseases. The technology is already in at least 14 clinical trials.

In one of them, Beam Therapeutics -- which Liu co-founded -- announced it had treated patients of AATD, a rare genetic disorder affecting the lungs and liver, with a single drug infusion.

While traditional gene therapies often disrupt faulty genes or work around them, base editing repairs the mutation itself.

"This was the first time that humans have corrected a mutation that causes a genetic disease in a patient," Liu said.

- Cystic fibrosis hope -

Base editing, quickly dubbed "CRISPR 2.0," can't fix every mutation.

About 70 percent of the roughly 100,000 known disease-causing mutations remain out of its reach, including those caused by missing or extra letters.

To expand the toolkit, Liu's lab introduced prime editing in 2019 -- a method capable of replacing entire sections of faulty DNA with corrected sequences.

If CRISPR is like scissors that cut DNA, and base editors are like using a pencil to correct individual letters, then prime editing is the equivalent of a word processor's "find and replace" function.

Creating this tool required a series of breakthroughs Liu's team describes as "small miracles." The result is, he said, "the most versatile way we know of to edit the human genome."

Among the targets Liu and his team have already pursued with prime editing: cystic fibrosis, a common genetic disease usually caused by three missing DNA letters that causes thick mucus buildup in the lungs and digestive system.

Liu's lab has made much of its work freely accessible, sharing DNA blueprints through a nonprofit library used by tens of thousands of labs worldwide.

"The science we create -- which is ultimately funded by society, through governments and donors -- ultimately goes back to benefit society."

This year's Breakthrough Prize awards come at a fraught moment for US science, as President Donald Trump's government strips funding for institutions like the National Institutes of Health (NIH).

"The NIH is a treasure, not just for this country but for the world," said Liu. "Trying to dismantle the heart of what supports science in this country is like burning your seed corn."

C.M.Harper--TFWP